Member Info for rivaldo

As well as Miton, Octopus and Patrick Evershed, Christopher Mills has also taken almost 8% of SDI via his Harwood Capital vehicle: Http://www.harwoodcapital.co.uk/ The SDI shareholder list is now something to behold for a £6.4m microcap: Shareholder Number of ordinary shares Percentage of issued share capital Octopus 7,706,430 12.01 Herald Investment Management 5,436,667 8.47 Harwood Capital 4,991,286 7.78 Milton Asset Management 4,991,286 7.78 Hargreave Hale 4,748,852 7.40 Dana Investments 3,496,494 5.45 Charles Stanley 3,051,631 4.76 Walker Crips 2,338,145 3.64

Fantastic :o)) I'm very happy with that, and it looks a done deal given the acceptances.

Boom :o))

The article notes a further 21% EPS forecast rise next year as well as this year, which would imply around 14p EPS. A P/E of say 16 would justify a 224p share price. Plus there's CDS in for free.

Excellent late recovery today. Finncap have reitereated their Buy, with a 45p target, and had this to say - they note that the results were actually ahead of expectations at around 2.35p EPS: "SimiGon*: Prelims (CORP) The global leader in simulation and training solutions provider has delivered strong earnings outperformance on the expected lower revenue. The company had previously flagged that delayed delivery of its major $6.7m prime contract won in 2013 would affect recognised revenue in FY 2015, and we reduced our expectations to $6.8m. In fact, SimiGon delivered $6.9m. Moreover, there was a dramatic reduction in overheads, across all areas but notably in R&D, which has led to a significant rise in operating margins (from 17% to 25%) and consequently adj. PBT rising 17% to $1.7m, well ahead of our forecast $1.5m. The adj. FD EPS of 3.3c is up 13%, again ahead of our 3.0c expectations. Trade debtors rose considerably, affecting cash conversion to such an extent there was a $1.7m outflow from operations. With the $0.3m dividend payment, this led to a $2.0m reduction in net cash to $7.4m at the December year end. $1.8m of the $3.7m trade receivables have been collected since the year end and management has maintained the dividend at the 6.0c declared last year. We reiterate our 45p target price."

Nice: Https://uk.finance.yahoo.com/news/buckle-4-hidden-growth-heroes-120040547.html "Buckle Up! 4 Hidden Growth Heroes Too Good To Miss By Royston Wild | Fool.co.uk 6 hours ago Today I'm taking the time to run the rule over four London small caps with what I see as electrifying earnings prospects... I believe industrial chemicals maker Carclo (LSE: CAR) should also continue to print excellent profits growth as demand from the car sector explodes. The firm's LED Technologies division builds lighting units for use in automobiles, and is rapidly expanding across Asia and the US to harness galloping demand for its products. And helped by a steady stream of new product rollouts, the Square Mile expects Carclo to follow a 19% earnings explosion in the period to March 2016 with an even better 21% advance in both 2017 and 2018. I believe subsequent earnings multiples of 11.6 times and 9.6 times make Carclo a steal given the company's rocketing momentum."

The last paragraph is particularly encouraging: Http://www.engineeringcapacity.com/news101/business-news/keeping-surgery-clean "Keeping surgery clean 29 Jan 2016 Synoptics innovative ProReveal test machines Midas Pattern Company are moulding stylish cover sets for test machines that serve to verify the cleanliness of surgical instruments after disinfection. The company services such as FASTrim rapid prototyping and MRIM production moulding have helped ensure Synoptics innovative ProReveal test machines remain clean. Richard Hopwood, R&D manager at Synoptics, said: "We worked closely with well-known academic research facilities on the cleanliness of surgical instruments based on conventional swab tests.� “The research proved that swab testing is not always sufficient. As a result we set about creating a test machine that could detect protein at much lower levels using extremely sensitive camera technology in combination with innovative lighting and filters,� he added. The ProReveal is a fluorescence-based, patented, protein detection test for checking the presence of residual protein on surgical instruments after going through a washer disinfector process. ProReveal can detect less than 50ng of residual protein, with results produced in under 5 minutes. The test delivers objective, visual and measurable results, removing doubt as to whether the washing decontamination process has left instruments demonstrably clean. To ensure that the design of this advanced product matched the high expectations of its concept, Synoptics turned to established product design partner, LA Design. The high resolution cameras being proposed for ProReveal can see an astonishing level of detail, but only if the illumination is correct – as a result, the covers have to be light-tight, which demands precision,� explained Les Stokes, one of the founders of LA Design. He added: “Beyond fit and function, the covers not only have to look stylish and approachable, but also have to relate to other products in the range, and help build the brand using an easy-to-understand design language.� These factors let to LA Design turning to Midas for the manufacture of the covers, a toolmaker and moulding shop it had used successfully before on a number of high profile projects. Timing was another issue as not only was Synoptics Health looking to get to market first, but the product was scheduled to appear at a forthcoming exhibition,� said Mr Stokes. With the prototype parts having served their purpose, production moulding is now being offered by Midas’ unique composite resin tooling system, which is used to produce high quality polyurethane mouldings. The set of covers for the ProReveal test machine comprise a number of separate mou

For an £8.5m m/cap at 17p you get: - I calculate around 2.2p EPS, omitting the tax credit - £5.3m net cash - another £1.3m of excess receivables over payables, so £6.6m of cash/receivables in total - a 0.6c dividend The revenue from the major $6.7m contract should smooth out the transition to high value, long term license contracts for this year, and there are plenty of contract win prospects mentioned in the narrative. Looks like SIM have a good handle on cost control too, with the large reduction in operating expenses, particularly R&D. In addition, I like the comments about: - increased recurring revenues from training - the growing involvement in drone/UAV systems

Good news today. The year end trading statement confirms trading in line with expectations of around 11.3p EPS - and a 4.2p dividend. With around consensus 12.1p EPS forecast for this year, CRE are on a P/E of just 8.7, with a 4% divi yield. Most importantly, the statement notes that clients' prospects have stabilised and improved.

Plenty to go for here imo. CAR were, at (say) 130p, trading on a current year P/E of 13.83. With 11.5p EPS forecast this year, an equivalent price target would be 160p. However, as recognition and awareness of CAR's business and track record grows, CAR should be attributed a higher rating. Finncap's 170p target would be welcome - however, this would still only be a P/E of 14.8. I would argue that any business which doubles its EPS in 3 years as CAR are forecast to do deserves a P/E of 18-20. Discount this somewhat for the gearing and the pension, and an appropriate P/E might be 16-18, or a 185p-207p share price.

Nice summary of today's results, with a 22p price target: http://www.proactiveinvestors.co.uk/companies/news/124796 Extract re broker comment: "Broker Cantor Fitzgerald said the miner was shaping up for a strong second half. Analyst Asa Bridle said he now expects the group to slightly exceed the top end of its annual production guidance (Cantor's estimate is 35,500 ounces) and to meet its target of all in sustaining costs (AISC) of being below US$1,000/oz in the second half, and between US$1,000-1,100/oz for the full year. "We expect EBITDA to rise from US$1m at the interim stage to US$7.9m by year end," he added. "Based on a conservative assumption of a US$1,200/oz gold price over the medium term, management are now assuming a stable production profile in the 30-35koz/year range," he noted. "However, if gold returns to US$1,300/oz, OMI would have the option of lifting production back to 50-55koz/year, but in the meantime the focus remains firmly on profitably over scale." The broker rates the shares a 'buy' and has an unchanged target price of 22p."

A $3.1m PAT for the quarter :o)) Admittedly this does include a $2.5m tax refund, but with AISC of only $978, and falling, a $600k PAT for the quarter is pretty impressive and should be a lot better this quarter with the higher gold price. And the $2.5m tax rebate will be received this quarter too, taking net cash to $4.1m excluding any improved cash from operations. Soon the cash pile will be not far off the £6.3m m/cap!

Very nice RNS's today indeed :o)) - trading slightly ahead of expectations - earnings-enhancing acquisition - more acquisitions in the pipeline - "strong backing from the Group's existing order book" - "the Board anticipates that both the first half year and full year results will show good progress against those achieved in 2015." The QRO acquisition is not only on a P/E of only around 8 assuming full earn-out - but QRO also bring in £0.9m cash compared to the £1.26m consideration!

Nice buying at 157p today.

Numis have raised their target price to 310p (from 275p): Http://www.americanbankingnews.com/2016/04/13/keywords-studios-plc-kws-price-target-raised-to-gbx-310/

SDI are imo on the cusp of a big turnaround, expedited by the big Sentek acquisition and some now outstanding institutional shareholders. This terrific article by Private Punter summarises things nicely: Http://www.cambridge-news.co.uk/Private-Punter-SDI-results-organic-growth/story-28485336-detail/story.html "Private Punter: SDI results show organic growth By Cambridge News | Posted: January 08, 2016 By Martin Flitton Scientific Digital Imaging (SDI) based at Nuffield Road here in Cambridge, has today announced its Interim results for the period ended 31 October 2015. Although the figures exclude the potentially transformational acquisition of Sentek, which was concluded a just a few days prior to period end, the numbers demonstrate continued progress within existing operations where organic growth of 15% was registered over the corresponding period. This was largely driven by Synoptics the largest division within the group, along with the Atik arm which serving the astronomy market now accounts for 25% of sales. Both played a part in assisting the jump in revenue from last years six months £3.18m to £3.67m, which also saw EBITDA increase by 69.8% to 0.4M. As for profits, the adjusted figure came out at £189k against the previous loss of £20k and would appear to set the company on track, for a full year in-line with Broker FinnCap's estimates of adjusted pre-tax profit of £0.7m. Although the reported period shows a net debt position of £1.4m due to costs incurred within the Sentek acquisition, that has since been eradicated due to the companies successful placing raising £2.5m post the period end. Looking ahead, SDI should now begin to benefit from Sentek's contribution, having previously stated that the Braintree based operation should provide it with repeat business in consumables bringing some welcome recurring revenue, along with an opportunity to leverage with existing distributors. There was also some other potentially interesting points to note, the first being a new version of the software for ProtoCOL 3 having been released, which provides the addition of testing for antibiotic resistance susceptibility. The same division is also developing a new system titled ChromaZona which is targeting antibiotic resistance testing in a clinical laboratories and is already undergoing clinical certification. Given the wide scale and growing concerns across this area there is clearly potential for SDI to capitalise on a growing market that includes hospital labs amongst others.... ....FinnCap retains a Buy stance and target price of 29p, which it describes as undemanding for a scientific instrumentation manufacturer. This is based on a 2017 EV/Sales of 1.8x and a PER of 12.4x at that price, which incidentally, compares favourably with the sector average of 18."

Tipped as a Buy by Questor in the Telegraph this morning - should see more buying as the day goes on: Http://www.telegraph.co.uk/business/2016/04/12/questor-share-tip-carclo-on-track-for-jump-in-profits/ "Carclo 143p +15.5p Questor says BUY Plastics specialist Carclo said it saw a much needed improvement in trading during the second half of the year, sending its shares more than 12pc higher. The company saw good demand in the US, which led to a stronger second half at its Technical Plastics division. Carclo’s LED lighting division also performed well in the six months to the end of March. The headlamps it makes are used in luxury car brands including Bugatti, Lamborghini and Aston Martin. The business continues to win new orders for its lights on a range of supercars, such as the new Aston Martin DB11, which is important as Led lighting contributes about a third of the group’s total revenue and more than half of the profits. The Precision Engineering reported a better second half, while its Carclo Diagnostics Solutions arm performed in line. The West Yorkshire-based company designs and manufactures plastics used in medical and electronic devices, and also produces LED lighting. Manufacturing sites have recently been expanded in Latrobe in the US, and a new facility in Taicang, China, is now fully operational. The company is currently expanding production sites in Bangalore, India and Tucson, Arizona. Management are confident the business is in line for the year ended March 31, with broker Peel Hunt expecting revenue up 8pc to £116m and pre-tax profits up 20pc to £8.5m giving 9.4p in earnings per share. The company is also well placed to drive a good set of results in the year ahead. Peel Hunt has forecast another 23pc jump in adjusted pre-tax profits to £10.5m giving 11.6p in earnings per share for the year to March 2017. Shares in the company look very conservatively rated trading on 14 times earnings for the year to March 2016, and falling to 11 times for the year after that. There is of course a risk of a downturn hitting supercar sales, but this company looks well placed. Buy."

Up nicely on good volumes yesterday. It's noticeable that any selling has been easily mopped up, and those institutions who didn't get enough shares in the oversubscribed placing are seemingly happy to top up at above the placing price in the market.

Nice start - up 1.5p on just a 1k buy at the full 155p offer price. No stock around?

DBay continue to buy and are up above 28% with 16.45m shares: Http://www.investegate.co.uk/creston-plc--cre-/rns/holding-s--in-company/201604130700089843U/ With Artemis now at almost 15% the two of them own 43% between them. I suspect some form of corporate action - including potentially a sale of the company - will follow at some point.